Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Up 56.7% in February

Connect Biopharma Holdings Limited (NASDAQ:CNTB) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 46,700 shares, a growth of 56.7% from the February 13th total of 29,800 shares. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.1% of the shares of the company are sold short.

Institutional Investors Weigh In On Connect Biopharma

Several large investors have recently modified their holdings of CNTB. Catalina Capital Group LLC purchased a new stake in Connect Biopharma in the fourth quarter worth $66,000. Choreo LLC bought a new stake in Connect Biopharma in the 4th quarter valued at about $204,000. Finally, Callan Capital LLC lifted its holdings in Connect Biopharma by 91.3% during the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock valued at $110,000 after purchasing an additional 38,177 shares during the last quarter. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Connect Biopharma Trading Up 0.7 %

Shares of NASDAQ CNTB traded up $0.01 during mid-day trading on Friday, reaching $0.86. 10,103 shares of the company’s stock were exchanged, compared to its average volume of 18,194. The firm has a 50-day moving average price of $0.96 and a two-hundred day moving average price of $1.11. Connect Biopharma has a 52 week low of $0.77 and a 52 week high of $2.66.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.